NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT04333706 2026-03-10
EMPOWER
University of Southern California
Phase 1/2 Recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT01061515 2025-09-17
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05821556 2025-07-29
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT02420509 2025-06-04
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
Terminated
NCT06942767 2025-04-27
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting